Shionogi & Co Ltd - Company Profile
Powered by
All the data and insights you need on Shionogi & Co Ltd in one report.
- Save hours of research time and resources with
our up-to-date Shionogi & Co Ltd Strategy Report
- Understand Shionogi & Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, pain/central nervous system (CNS), infectious diseases and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.
Shionogi & Co Ltd premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
Prescription Drugs: | Contract Manufacturing Services | Rizmoic |
Crestor | Symproic | |
Cymbalta | Simploic | |
XYZ | XYZ | |
XYZ | XYZ | |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In April, Taiwan Shionogi & Co., Ltd. received approval for a supplemental new drug application for Xofluza (baloxavir marboxil) for the treatment and postexposure prophylaxis for influenza virus infection for pediatrics. |
2024 | Contracts/Agreements | In March, the company announced a collabration with Nagasaki University to commence drug discovery research in malaria. |
2024 | Contracts/Agreements | In February, the company and FRONTEO entered into a strategic business partnership agreement for the dementia-related AI program and depression-related AI program. |
Competitor Comparison
Key Parameters | Shionogi & Co Ltd | Takeda Pharmaceutical Co Ltd | Daiichi Sankyo Co Ltd | Chugai Pharmaceutical Co Ltd | Santen Pharmaceutical Co Ltd |
---|---|---|---|---|---|
Headquarters | Japan | Japan | Japan | Japan | Japan |
City | Osaka-Shi | Chuo-Ku | Chuo-Ku | Chuo-Ku | Osaka-Shi |
State/Province | Osaka | Tokyo | Tokyo | Tokyo | Osaka |
No. of Employees | 5,680 | 49,095 | 17,435 | 7,604 | 4,144 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Takuko Sawada | Director; Vice Chairman | Executive Board | 2022 | - |
Isao Teshirogi, Ph.D. | Chief Executive Officer; President; Director | Executive Board | 2008 | - |
Tatsumori Yoshida | Chief Executive Officer - Ping An Shionogi Company Ltd and Ping An Shionogi (Hong Kong) Company Ltd; Chairman - Ping An Shionogi Company Ltd and Ping An Shionogi (Hong Kong) Company Ltd; Corporate Officer | Executive Board | 2018 | - |
Koji Hanasaki, Ph.D. | Corporate Officer; Senior Executive Officer; Senior Vice President - Global Business Division | Senior Management | 2018 | - |
Noriyuki Kishida | Senior Exective Officer; Senior Vice President - Corporate Supervisory Unit | Senior Management | 2020 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer